The National Home Infusion Association has announced the finalists for its 2025 Exhibitor Innovation Award. The award recognizes groundbreaking products or services that advance the home and alternate site infusion industry.
https://doi.org/10.70776/TMPJ4448
Yoselin Flores, PharmD Option Care Health | Jessica Monczka, RD, CNSC, FASPEN Option Care Health | Maria Giannakos, PharmD, MBA, BCPS, BCSCP, FNHIA Option Care Health | Annemarie Hocking, PharmD Option Care Health | Suzanne Kluge, BSPharm, MBA, BCSCP, FNHIA Option Care Health
The primary objective of this study was to compare the resources utilized when using a lipid risk screening tool versus the resources utilized previously without the use of a lipid risk screening tool. Specifically, this study assessed nursing time and drug costs related to the dispensing of anaphylaxis kits. The secondary objective was to assess the tolerability of ILE first doses in the home. It was hypothesized that ILE first doses in the home would be well tolerated after clinical review of patients using the lipid risk screening tool.
Recognizing Excellence in Home and Specialty Infusion Research: The NHIF Outstanding Abstract Achievement Award
The National Home Infusion Foundation (NHIF) is proud to announce the finalists for the 2025 Outstanding Abstract Achievement Award, a recognition of groundbreaking research that advances best practices in home and specialty infusion. Each year, this award highlights innovative approaches, quality improvements, and solutions to critical challenges within the field.
https://doi.org/10.70776/TAMR6122
Gerome Vallejos, MD, Harvard Medical School, Division of Neuroimmunology and Neuroinfectious Disease, Department of Neurology | Gabriela Romanow, Harvard Medical School, Division of Neuroimmunology and Neuroinfectious Disease, Department of Neurology | Michael Levy, MD, PhD, Harvard Medical School Division of Neuroimmunology and Neuroinfectious Disease, Department of Neurology
To determine whether people with neuromyelitis optica spectrum disorder (NMOSD) prefer to receive inebilizumab infusions at home versus in an infusion center or hospital, and to assess how that choice affects their quality of life.
NHIA announces two new companies will join its 2024-2025 Board of Directors. Board members serve 3-year terms as representatives for their NHIA member organization. Joining the NHIA Board of Directors are Pentec Health, represented by Matthew Deans, CEO and Vital Care Infusion Services, represented by Logan Davis, Executive VP of Trade Relations and Strategy. In addition to the newly installed members, Upstate Home Care, Froedtert Health, and Amerita were elected to additional terms.
The National Home Infusion Association (NHIA) is proud to announce that Mitra Gavgani, PharmD is the recipient of the 2025 Gene Graves Lifetime Achievement Award.
The National Home Infusion Association (NHIA) applauds the re-introduction of The Preserving Patient Access to Home Infusion Act – bipartisan, bicameral legislation that will ensure Medicare patients can receive the intravenous (IV) medications they need while at home.
NHIF is proud to announce that Maritza DeGagne, RPh is the recipient of the 2025 Lynn Giglione Women in Leadership Award, which recognizes and honors trail-blazing and emerging women leaders who have demonstrated exemplary service to patients and their peers while promoting the mission of NHIF.
The National Home Infusion Association (NHIA) is pleased to announce the 2025 Fellow Program (FNHIA) cohort, made up of highly accomplished home and alternate site infusion professionals.
The prestigious NHIA Fellow Program aims to advance the home and alternate site infusion profession by recognizing the contributions and achievements of highly accomplished individuals.
The National Home Infusion Foundation (NHIF) announces the finalists for its Outstanding Abstract Achievement Award for 2025. The authors of the following 5 poster abstracts will present an overview of their research project and summarize their findings during a special clinical webinar and a panel of judges will select the award recipient.
NHIA submitted comments to CMS on its Draft Medicare Transaction Facilitator (MTF) Agreements, which will be used to implement negotiated prices for drugs under the Medicare Drug Price Negotiation Program.
NHIA is accepting applications for members of the association’s Board of Directors. Board members serve 3-year terms as representatives for their NHIA member organization. Seats are only open to provider members and are assigned at the organization level.
The National Home Infusion Association (NHIA) expressed deep concern today regarding the recently proposed government funding bill, which includes major changes to the qualifying criteria for drugs under Medicare’s home infusion benefit but fails to address the underlying flaws that have plagued the program. Without fixing the structure of the benefit, Medicare beneficiaries in need of home infusions for treatment of a variety of medical conditions, including rare diseases, are unlikely to gain access to home-based care.
An independent analysis by Magnolia Market Access estimates that changes proposed by NHIA to the Preserving Patient Access to Home Infusion Act to expand Medicare Part B home infusion therapy services coverage to anti-infectives, and bundle payments for disposable supplies with the services payment would generate significant savings for Medicare.
The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, are pleased to announce the addition of Melinta to NHIA’s Future of Infusion Advisory Council (FIAC).
https://doi.org/10.70776/MIOB6792
Angela Nguyen, PharmD Fairview Home Infusion | R. May O’Donnell, MS Fairview Pharmacy Services | C. Brett Benfield PharmD, MS, FNHIA Fairview Infusion Consulting Services | Marrea Peters, PharmD Fairview Home Infusion | Alicia L. Zagel, PhD, MPH Fairview Pharmacy Services
Oncology infusions are a cornerstone of cancer treatment, often administered in hospitalbased outpatient departments (HOPDs) due to the controlled environment they offer. However, with the rise of patient-centered care and cost reduction efforts, home infusion services are an increasingly viable alternative for oncology treatments, though some professional groups have concerns about safety. To address these concerns, this study compares safety outcomes of oncology infusions administered through home infusion (HI) to those administered in HOPDs.
https://doi.org/10.70776/JECB9600
Katherine Yang, PharmD, BCPS | Wendy Morimoto, PharmD | Kristina Wong, PharmD | Mehrnaz Zahiri, PharmD | Meredith Silverman, MD
This study evaluates the cost differences between administering and monitoring vancomycin and daptomycin in a home infusion pharmacy (HIP) setting. Both antibiotics are widely used for treating methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive infections in outpatient parenteral antibiotic therapy (OPAT), but vancomycin requires more intensive therapeutic monitoring than daptomycin. The study aims to quantify pharmacist time spent monitoring patients, lab costs, and overall drug administration costs associated with each therapy in a HIP serving 16 medical centers in Northern California.
The National Home Infusion Association has announced the finalists for its 2025 Exhibitor Innovation Award. The award recognizes groundbreaking products or services that advance the home and alternate site infusion industry.
https://doi.org/10.70776/TMPJ4448
Yoselin Flores, PharmD Option Care Health | Jessica Monczka, RD, CNSC, FASPEN Option Care Health | Maria Giannakos, PharmD, MBA, BCPS, BCSCP, FNHIA Option Care Health | Annemarie Hocking, PharmD Option Care Health | Suzanne Kluge, BSPharm, MBA, BCSCP, FNHIA Option Care Health
The primary objective of this study was to compare the resources utilized when using a lipid risk screening tool versus the resources utilized previously without the use of a lipid risk screening tool. Specifically, this study assessed nursing time and drug costs related to the dispensing of anaphylaxis kits. The secondary objective was to assess the tolerability of ILE first doses in the home. It was hypothesized that ILE first doses in the home would be well tolerated after clinical review of patients using the lipid risk screening tool.
Recognizing Excellence in Home and Specialty Infusion Research: The NHIF Outstanding Abstract Achievement Award
The National Home Infusion Foundation (NHIF) is proud to announce the finalists for the 2025 Outstanding Abstract Achievement Award, a recognition of groundbreaking research that advances best practices in home and specialty infusion. Each year, this award highlights innovative approaches, quality improvements, and solutions to critical challenges within the field.
https://doi.org/10.70776/TAMR6122
Gerome Vallejos, MD, Harvard Medical School, Division of Neuroimmunology and Neuroinfectious Disease, Department of Neurology | Gabriela Romanow, Harvard Medical School, Division of Neuroimmunology and Neuroinfectious Disease, Department of Neurology | Michael Levy, MD, PhD, Harvard Medical School Division of Neuroimmunology and Neuroinfectious Disease, Department of Neurology
To determine whether people with neuromyelitis optica spectrum disorder (NMOSD) prefer to receive inebilizumab infusions at home versus in an infusion center or hospital, and to assess how that choice affects their quality of life.
NHIA announces two new companies will join its 2024-2025 Board of Directors. Board members serve 3-year terms as representatives for their NHIA member organization. Joining the NHIA Board of Directors are Pentec Health, represented by Matthew Deans, CEO and Vital Care Infusion Services, represented by Logan Davis, Executive VP of Trade Relations and Strategy. In addition to the newly installed members, Upstate Home Care, Froedtert Health, and Amerita were elected to additional terms.
The National Home Infusion Association (NHIA) is proud to announce that Mitra Gavgani, PharmD is the recipient of the 2025 Gene Graves Lifetime Achievement Award.
The National Home Infusion Association (NHIA) applauds the re-introduction of The Preserving Patient Access to Home Infusion Act – bipartisan, bicameral legislation that will ensure Medicare patients can receive the intravenous (IV) medications they need while at home.
NHIF is proud to announce that Maritza DeGagne, RPh is the recipient of the 2025 Lynn Giglione Women in Leadership Award, which recognizes and honors trail-blazing and emerging women leaders who have demonstrated exemplary service to patients and their peers while promoting the mission of NHIF.
The National Home Infusion Association (NHIA) is pleased to announce the 2025 Fellow Program (FNHIA) cohort, made up of highly accomplished home and alternate site infusion professionals.
The prestigious NHIA Fellow Program aims to advance the home and alternate site infusion profession by recognizing the contributions and achievements of highly accomplished individuals.
The National Home Infusion Foundation (NHIF) announces the finalists for its Outstanding Abstract Achievement Award for 2025. The authors of the following 5 poster abstracts will present an overview of their research project and summarize their findings during a special clinical webinar and a panel of judges will select the award recipient.
NHIA submitted comments to CMS on its Draft Medicare Transaction Facilitator (MTF) Agreements, which will be used to implement negotiated prices for drugs under the Medicare Drug Price Negotiation Program.
NHIA is accepting applications for members of the association’s Board of Directors. Board members serve 3-year terms as representatives for their NHIA member organization. Seats are only open to provider members and are assigned at the organization level.
The National Home Infusion Association (NHIA) expressed deep concern today regarding the recently proposed government funding bill, which includes major changes to the qualifying criteria for drugs under Medicare’s home infusion benefit but fails to address the underlying flaws that have plagued the program. Without fixing the structure of the benefit, Medicare beneficiaries in need of home infusions for treatment of a variety of medical conditions, including rare diseases, are unlikely to gain access to home-based care.
An independent analysis by Magnolia Market Access estimates that changes proposed by NHIA to the Preserving Patient Access to Home Infusion Act to expand Medicare Part B home infusion therapy services coverage to anti-infectives, and bundle payments for disposable supplies with the services payment would generate significant savings for Medicare.
The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, are pleased to announce the addition of Melinta to NHIA’s Future of Infusion Advisory Council (FIAC).
https://doi.org/10.70776/MIOB6792
Angela Nguyen, PharmD Fairview Home Infusion | R. May O’Donnell, MS Fairview Pharmacy Services | C. Brett Benfield PharmD, MS, FNHIA Fairview Infusion Consulting Services | Marrea Peters, PharmD Fairview Home Infusion | Alicia L. Zagel, PhD, MPH Fairview Pharmacy Services
Oncology infusions are a cornerstone of cancer treatment, often administered in hospitalbased outpatient departments (HOPDs) due to the controlled environment they offer. However, with the rise of patient-centered care and cost reduction efforts, home infusion services are an increasingly viable alternative for oncology treatments, though some professional groups have concerns about safety. To address these concerns, this study compares safety outcomes of oncology infusions administered through home infusion (HI) to those administered in HOPDs.
https://doi.org/10.70776/JECB9600
Katherine Yang, PharmD, BCPS | Wendy Morimoto, PharmD | Kristina Wong, PharmD | Mehrnaz Zahiri, PharmD | Meredith Silverman, MD
This study evaluates the cost differences between administering and monitoring vancomycin and daptomycin in a home infusion pharmacy (HIP) setting. Both antibiotics are widely used for treating methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive infections in outpatient parenteral antibiotic therapy (OPAT), but vancomycin requires more intensive therapeutic monitoring than daptomycin. The study aims to quantify pharmacist time spent monitoring patients, lab costs, and overall drug administration costs associated with each therapy in a HIP serving 16 medical centers in Northern California.
